Hong-Uyen Hua, MD
Retina Specialist · Miami, FLNPI 1497287866
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by AbbVie at 25.8% of the total. 2025 is the largest year on record at $25,211, more than ten times the $1,592 reported in 2019.
Across 137 payments — averaging $325.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Amgen$10K
- Alcon$10K
- Apellis Pharmaceuticals, Inc.$4K
- Genentech USA, Inc.$3K
- Alimera Sciences, Inc.$3K
- plus $3K from 12 others
Across 7 payments — averaging $5885.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$41K
- Novartis$594
What the payments were for
- Consulting fees$25,38557%
- Speaking & faculty fees$6,62115%
- Travel & lodging$4,48110%
- Food & beverage$8,06018%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $11,488 |
| Amgen | 4 | $10,018 |
| Alcon | 43 | $9,556 |
| Apellis Pharmaceuticals, Inc. | 17 | $4,066 |
| Genentech USA, Inc. | 12 | $3,065 |
| Alimera Sciences, Inc. | 7 | $2,944 |
| Dutch Ophthalmic, USA | 6 | $1,309 |
| Oculus Surgical Inc. | 5 | $462 |
| Bausch & Lomb Americas Inc. | 6 | $306 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $250 |
| Novartis | 2 | $250 |
| Regeneron Healthcare Solutions, Inc. | 5 | $238 |
| Astellas Pharma US Inc | 3 | $215 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $162 |
| Regeneron | 1 | $142 |
| Glaukos Corporation | 1 | $33 |
| Harrow Eye, LLC | 1 | $29 |
| Eyepoint US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,549 in reported general payments places this provider in the 85th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 76 | $2,853 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $349 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 29 | $312 |
| Ofloxacin | 18 | $199 |
| Latanoprost | 14 | $57 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Miami
- Thomas AlbiniMiami$281K
- Audina BerrocalMiami$210K
- Philip RosenfeldMiami$206K
- Nicolas YannuzziMiami$60K
- Justin TownsendMiami$40K
- Harry FlynnMiami$7K
- Sunil GuptaPensacola$1.8M
- Joseph NezgodaWest Palm Beach$600K
- Eduardo UchiyamaFt Lauderdale$356K
- John MyersPensacola$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.